Headache News and Research

Latest Headache News and Research

Romark announces results from NT-300 Phase 2B-3 trial on influenza

Romark Laboratories announced that results of a large Phase 2B-3 US clinical trial of its new flu drug, NT-300 (nitazoxanide), will be presented as an oral late-breaking communication at the 49th Annual Meeting of the Infectious Diseases Society of America (IDSA) being held in Boston, October 20-23, 2011.

22 Oct 2011

Headache are among the top reasons for medical evacuation of soldiers

Headaches, a virtually universal human complaint at one time or another, are among the top reasons for medical evacuation of military personnel from Iraq and Afghanistan, and for ongoing depletion of active-duty ranks in those countries, according to research led by Johns Hopkins specialists. Just one-third of soldiers sent home because of headaches return to duty in either place, the research shows.

14 Oct 2011

Merck announces results from ISENTRESS Phase III combination study on HIV-1

Merck, known as MSD outside the United States and Canada, today announced results of new exploratory pre-specified analyses from the ongoing STARTMRK Phase III study of its integrase inhibitor ISENTRESS (raltegravir) Tablets in combination therapy compared to efavirenz in combination therapy in previously untreated adult HIV-1-infected patients.

14 Oct 2011

U of U researchers to investigate long-term effects of TBI in soldiers

Traumatic brain injury (TBI) affects many Americans: high school athletes, drivers and passengers in motor vehicle accidents, and victims of domestic violence, to name a few. Some of the most striking effects of brain injury are seen in our soldiers and veterans returning from Iraq and Afghanistan. Two University of Utah researchers are teaming up with the Department of Defense to investigate the long-term effects of TBI in these returning soldiers.

13 Oct 2011

Walgreens Flu Impact Report

The typical flu season always coincides with the busiest travel period of the year, and last season that spelled trouble for more than 3 million U.S. vacationers whose trips were interrupted by flu-related illness, the Walgreens Flu Impact Report suggests.

12 Oct 2011

Shield commences two ST10 Phase 3 studies in iron deficiency anaemia

Shield Therapeutics (Shield), the independent specialty pharmaceutical company focused on the development and commercialisation of late-stage, mineral-derived hospital pharmaceuticals which address areas of high unmet medical need, today announced that the first patients have been treated in the two Phase 3 clinical studies of ST10 for the treatment of iron deficiency anaemia (IDA) in subjects with inflammatory bowel disease.

12 Oct 2011

Merck’s diabetes combo pill gets FDA nod

The U.S. Food and Drug Administration (FDA) has approved Merck & Co.’s Juvisync diabetes drug, a combination pill for type 2 diabetes. Juvisync combines two Merck drugs already on the market, 1) glucose-lowering Januvia (Sitagliptin) medication and 2) cholesterol-lowering Zocor (Simvastatin).

10 Oct 2011

Boehringer Ingelheim receives FDA approval for COMBIVENT RESPIMAT to treat COPD

Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved COMBIVENT RESPIMAT, a new, propellant-free inhaler product that uses a slow-moving mist to deliver the same active ingredients of COMBIVENT Inhalation Aerosol in a metered dose inhaler.

10 Oct 2011

Merck receives FDA approval for JUVISYNC to treat type 2 diabetes

Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved JUVISYNC(sitagliptin and simvastatin), a new treatment for type 2 diabetes that combines the glucose-lowering medication sitagliptin, the active component of JANUVIA (sitagliptin), with the cholesterol-lowering medication ZOCOR.

10 Oct 2011

Sports head injuries among teens and youth on the rise

According to a latest CDC report, there was about a 60% increase in the estimated number of concussions and other traumatic brain injuries (TBI) seen among young athletes during the past decade.

9 Oct 2011

First combination drug to treat type 2 diabetes and high cholesterol receives FDA approval

The U.S. Food and Drug Administration today approved Juvisync (sitagliptin and simvastatin), a fixed-dose combination (FDC) prescription medication that contains two previously approved medicines in one tablet for use in adults who need both sitagliptin and simvastatin.

7 Oct 2011

The US Oncology Network affiliate treats advanced prostate cancer patients with PROVENGE

David, a 67-year-old father of three and soon to be first-time grandfather, felt too young to be diagnosed with prostate cancer. "I felt great," he said. "I had no symptoms." David, under the advisement of his oncologist, decided to be treated with PROVENGE (sipuleucel-T), the first in a new therapeutic class known as autologous cellular immunotherapies.

1 Oct 2011

Bristol-Myers to present abstracts on research in liver disease at The Liver Meeting 2011

Bristol-Myers Squibb Company announced today that 22 abstracts on the Company's research in liver disease have been accepted for presentation at The Liver Meeting 2011, the 62nd annual meeting of the American Association for the Study of Liver Diseases, in San Francisco, November 4 - 8.

1 Oct 2011

Pfizer releases Phase III study results comparing VFEND-ERAXIS combination to VFEND for IA

Pfizer Inc. today reported the top-line results of an international Phase III clinical trial which compared the combination of VFEND (voriconazole) and ERAXISTM (anidulafungin) to VFEND monotherapy for primary therapy of invasive aspergillosis, a life-threatening invasive fungal infection that can develop as a complication in patients with compromised immune systems.

1 Oct 2011

New analyses from Phase III studies of VICTRELIS to be presented at AASLD 2011

Merck, known as MSD outside of the United States and Canada, announced today that several new analyses from Phase III studies of VICTRELIS (boceprevir), the company's first-in-class, oral hepatitis C virus NS3/4A protease inhibitor will be presented at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases.

1 Oct 2011

Baxter seeks European marketing authorization for HyQ to treat PI

Baxter International Inc. announced today that it has submitted an application to the European Medicines Agency's Committee for Human Medicinal Products seeking marketing authorization for HyQ. HyQ is Baxter's investigational immunoglobulin (IG) therapy administered subcutaneously and facilitated by recombinant human hyaluronidase, a dispersion and permeation enhancer, for use in patients with primary immunodeficiencies.

From Baxter International Inc. 1 Oct 2011

Cincinnati Children's to conduct first medication clinical trial for pediatric migraine

Cincinnati Children's Hospital Medical Center has received a $12 million grant from the National Institutes of Health to conduct the first clinical trial to determine the medication of choice for preventing migraines in children and teens.

30 Sep 2011

Cincinnati Children's to conduct first pediatric migraine medicine clinical trial

29 Sep 2011

Columbia University receives CFI grant to investigate causes of chronic fatigue syndrome

The Chronic Fatigue Initiative (CFI) - a new privately funded research directive focused on chronic fatigue syndrome - announced a substantial grant to a Columbia University research team to investigate the role of pathogens in causing chronic fatigue syndrome. The pathogen discovery and pathogenesis program will be led by Drs. Ian Lipkin and Mady Hornig of the Center for Infection and Immunity.

28 Sep 2011

Methodist Hospital internist offers few simple suggestions to prevent cold and flu

The first few breezes of fall bring with them not only the promise of a welcome change in season, but also the threat of colds and flu. Dr. Joshua Septimus, an internist at The Methodist Hospital in Houston, offers a few simple suggestions to protect you and your family this cold and flu season. "The most useful tip I can pass along is to wash your hands," says Septimus. "It sounds so simple, but it is truly the most important thing you can do to protect yourself."

27 Sep 2011

Headache News and Research

Latest Headache News and Research

Romark announces results from NT-300 Phase 2B-3 trial on influenza

Headache are among the top reasons for medical evacuation of soldiers

Merck announces results from ISENTRESS Phase III combination study on HIV-1

U of U researchers to investigate long-term effects of TBI in soldiers

Walgreens Flu Impact Report

Shield commences two ST10 Phase 3 studies in iron deficiency anaemia

Merck’s diabetes combo pill gets FDA nod

Boehringer Ingelheim receives FDA approval for COMBIVENT RESPIMAT to treat COPD

Merck receives FDA approval for JUVISYNC to treat type 2 diabetes

Sports head injuries among teens and youth on the rise

First combination drug to treat type 2 diabetes and high cholesterol receives FDA approval

The US Oncology Network affiliate treats advanced prostate cancer patients with PROVENGE

Bristol-Myers to present abstracts on research in liver disease at The Liver Meeting 2011

Pfizer releases Phase III study results comparing VFEND-ERAXIS combination to VFEND for IA

New analyses from Phase III studies of VICTRELIS to be presented at AASLD 2011

Baxter seeks European marketing authorization for HyQ to treat PI

Cincinnati Children's to conduct first medication clinical trial for pediatric migraine

Cincinnati Children's to conduct first pediatric migraine medicine clinical trial

Columbia University receives CFI grant to investigate causes of chronic fatigue syndrome

Methodist Hospital internist offers few simple suggestions to prevent cold and flu

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Headache News and Research

Latest Headache News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in